Literature DB >> 17974991

Inhibition of nuclear factor-kappaB DNA binding by organoselenocyanates through covalent modification of the p50 subunit.

Kun-Ming Chen1, Thomas E Spratt, Bruce A Stanley, Dan A De Cotiis, Maria C Bewley, John M Flanagan, Dhimant Desai, Arunangshu Das, Emerich S Fiala, Shantu Amin, Karam El-Bayoumy.   

Abstract

Most known chemopreventive agents including certain selenium compounds suppress the activation of the nuclear factor kappaB (NF-kappaB), but the mechanisms remain largely elusive. Toward this end, we initially showed that the inhibition of NF-kappaB DNA binding by benzyl selenocyanate (BSC) and 1,4-phenylenebis(methylene)selenocyanate (p-XSC) was reversed by the addition of DTT; this suggests the formation of DTT-reducible selenium-sulfur bonds between selenocyanate moieties and cysteine residues in NF-kappaB (p50) protein. Furthermore, the inhibitory effect of selenocyanates on NF-kappaB was not altered in the presence of physiologic level of reduced glutathione (1 mmol/L), suggesting that selenocyanates can also inhibit NF-kappaB in vivo. Using both matrix-assisted laser desorption/ionization-time of flight and tandem mass spectrometry fragmentation, we showed for the first time that the Cys(62) residue in the active site of NF-kappaB (p50) protein was modified by BSC through the formation of a selenium-sulfur bond. In addition, p-XSC-bound NF-kappaB (p50) protein was also detected by a radiotracer method. To provide further support, molecular models of both BSC and p-XSC positioned in the DNA binding pocket of the p50 were constructed through the covalent modification of Cys(62); the models reveal that DNA substrate could be hindered to enter its DNA binding region. This study shows for the first time that BSC and p-XSC may exert their chemopreventive activity, at least in part, by inhibiting NF-kappaB through covalent modification of Cys(62) of the p50 subunit of NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17974991     DOI: 10.1158/0008-5472.CAN-07-2510

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Selenium-responsive proteins in the sera of selenium-enriched yeast-supplemented healthy African American and Caucasian men.

Authors:  Raghu Sinha; Indu Sinha; Nicole Facompre; Stephen Russell; Richard I Somiari; John P Richie; Karam El-Bayoumy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-19       Impact factor: 4.254

2.  Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds.

Authors:  Tsutomu Shimada; Norie Murayama; Katsuhiro Tanaka; Shigeo Takenaka; F Peter Guengerich; Hiroshi Yamazaki; Masayuki Komori
Journal:  Chem Res Toxicol       Date:  2011-07-20       Impact factor: 3.739

3.  Serum cytokine analysis in a positive chemoprevention trial: selenium, interleukin-2, and an association with squamous preneoplastic disease.

Authors:  Mark J Roth; Hormuzd A Katki; Wen-Qiang Wei; You-Lin Qiao; Rachel Bagni; Guo-Qing Wang; Denise Whitby; Zhi-Wei Dong; Mitchell H Gail; Paul J Limburg; Carol A Giffen; Philip R Taylor; Sanford M Dawsey
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-29

4.  1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells.

Authors:  Nicole D Facompre; Karam El-Bayoumy; Yuan-Wan Sun; John T Pinto; Raghu Sinha
Journal:  Cancer Prev Res (Phila)       Date:  2010-07-06

5.  PhICl2-Mediated Regioselective and Electrophilic Oxythio/Selenocyanation of o-(1-Alkynyl)benzoates: Access to Biologically Active S/SeCN-Containing Isocoumarins.

Authors:  Shanqing Tao; Aiwen Huo; Yan Gao; Xiangyang Zhang; Jingyue Yang; Yunfei Du
Journal:  Front Chem       Date:  2022-05-18       Impact factor: 5.545

6.  Targeting Akt3 signaling in malignant melanoma using isoselenocyanates.

Authors:  Arati Sharma; Arun K Sharma; Subbarao V Madhunapantula; Dhimant Desai; Sung Jin Huh; Paul Mosca; Shantu Amin; Gavin P Robertson
Journal:  Clin Cancer Res       Date:  2009-02-10       Impact factor: 12.531

7.  Modulations of benzo[a]pyrene-induced DNA adduct, cyclin D1 and PCNA in oral tissue by 1,4-phenylenebis(methylene)selenocyanate.

Authors:  Kun-Ming Chen; Peter G Sacks; Thomas E Spratt; Jyh-Ming Lin; Telih Boyiri; Joel Schwartz; John P Richie; Ana Calcagnotto; Arunangshu Das; James Bortner; Zonglin Zhao; Shantu Amin; Joseph Guttenplan; Karam El-Bayoumy
Journal:  Biochem Biophys Res Commun       Date:  2009-04-01       Impact factor: 3.575

8.  Lipoxygenase catalyzed metabolites derived from docosahexaenoic acid are promising antitumor agents against breast cancer.

Authors:  Kun-Ming Chen; Henry Thompson; John P Vanden-Heuvel; Yuan-Wan Sun; Neil Trushin; Cesar Aliaga; Krishne Gowda; Shantu Amin; Bruce Stanley; Andrea Manni; Karam El-Bayoumy
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

Review 9.  Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges.

Authors:  Bocheng Wu; Quaovi H Sodji; Adegboyega K Oyelere
Journal:  Cancers (Basel)       Date:  2022-01-22       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.